After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries
Authors' conclusion
After failing the first JAKi, cycling JAKi and switching to a bDMARD appear to have similar effectiveness.
Study context
- Population
- Patients with rheumatoid arthritis (RA) after failure of the first Janus kinase inhibitors (JAKi), 17 national registries (JAK-pot collaboration)
- Participants
- 365 vs 1,635
- Exposure
- Cycling JAKi vs switching to biologic disease-modifying antirheumatic drug (bDMARD) after failure of first JAKi
- Cyclingn = 365
- Switchingn = 1,635reference
- Outcome
- Drug retention after second treatment initiation
- Follow-up
- 2 years
Methodological detailsinternational collaboration of 17 national registries (JAK-pot), prospectively collected data, Cox regression adjusting for potential confounders
- International collaboration of 17 national registries (JAK-pot)
- Prospectively collected data
- Cox regression adjusting for potential confounders
Main finding
As reported in the abstract
Drug retention
- Similar observed retention rates in both strategies after 2 years
- Adjusted analysis: cycling associated with higher retention
- Cycling vs Switching: P = 0.04
Observational data: associations, not effects.
Further findings
Improvement in Clinical Disease Activity Index (CDAI) over time
- Similar in both strategies
Original publication
After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries. Ann Rheum Dis. Published 13 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →